Results 21 to 30 of about 6,879 (152)

Neuroborreliosis in patient with aplastic anaemia secondary to therapy with ticlopidine [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2010
Introduction. Aplastic anaemia is a rare but potentially fatal complication of treatment with ticlopidine. Case Outline. We present a 55-year-old male with aplastic anaemia which developed after 45 days of the therapy with 200 mg ticlopidine to ...
Čolović Milica, Palibrk Vuk, Vidović Ana, Čolović Nataša, Bumbaširević Ljiljana   +4 more
doaj   +1 more source

Ticlopidine-induced subacute cutaneous lupus erythematosus: A case report and literature review

Dermatologica Sinica, 2014
Many drugs have been reported to induce lupus in a minority of patients. Ticlopidine hydrochloride inhibits platelet aggregation and is widely used for the prevention of thrombosis. There have been only a few reports of ticlopidine-induced lupus.
Yi-Ching Chen, Yu-Hung Wu
doaj   +1 more source

Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?

Current Controlled Trials in Cardiovascular Medicine, 2000
In the Ticlid or Plavix Post-Stents (TOPPS) trial, 1016 patients undergoing successful coronary stent placement were randomized to receive aspirin and either ticlopidine or clopidogrel.
Berger Peter B
doaj   +1 more source

Efficacy of aspirin, clopidogrel, and ticlopidine in stroke prevention: A population-based case-cohort study in Taiwan.

PLoS ONE, 2020
BackgroundIn real-world practice settings, there is insufficient evidence on the efficacy of antiplatelet drugs, including clopidogrel, aspirin, and ticlopidine, in stroke prevention.PurposeTo compare the efficacies between aspirin and clopidogrel and ...
Yi-Sin Wong, Ching-Fang Tsai, Yueh-Han Hsu, Cheung-Ter Ong   +3 more
doaj   +1 more source

Repurposing the Antiplatelet Agent Ticlopidine to Counteract the Acute Phase of ER Stress Condition: An Opportunity for Fighting Coronavirus Infections and Cancer

Molecules, 2022
Different pathological conditions, including viral infections and cancer, can have a massive impact on the endoplasmic reticulum (ER), causing severe damage to the cell and exacerbating the disease.
Anna Tesei, Michela Cortesi, Martina Bedeschi, Noemi Marino, Giacomo Rossino, Roberta Listro, Daniela Rossi, Pasquale Linciano, Simona Collina   +8 more
doaj   +1 more source

Sensitive Voltammetric Determination of Ticlopidine in Pharmaceuticals Employing a Multi-Walled Carbon Nanotubes Paste Electrode

Orbital: The Electronic Journal of Chemistry, 2016
A sensitive analytical procedure has been developed for the determination of ticlopidine using a multi-walled carbon nanotubes paste electrode (MWCNTsPE). Direct oxidation of analyte was observed by cyclic voltammetry as evidenced by the presence of well-
Igor Rebech, Jessica Scremin, César Ricardo Teixeira Tarley, Elen Romão Sartori   +3 more
doaj   +3 more sources

Highly productive and scalable approach to synthesize ticlopidine: A potent thienopyridine anti-platelet aggregation drug

Heliyon, 2020
Ticlopidine (trade name Ticlid), an acidic thienopyridine derivative, is an effective, well-known and long-acting inhibitor of platelet aggregation.
Muhammad Faisal, Quret ul Aein, Aamer Saeed, Amara Mumtaz, Fayaz Ali Larik   +4 more
doaj   +1 more source

Ticlopidine in Its Prodrug Form Is a Selective Inhibitor of Human NTPDase1

Mediators of Inflammation, 2014
Nucleoside triphosphate diphosphohydrolase-1 (NTPDase1), like other ectonucleotidases, controls extracellular nucleotide levels and consequently their (patho)physiological responses such as in thrombosis, inflammation, and cancer.
Joanna Lecka, Michel Fausther, Beat Künzli, Jean Sévigny   +3 more
doaj   +1 more source

Agranulocytosis and hepatic toxicity with ticlopidine therapy: a case report

Journal of Medical Case Reports, 2010
Introduction Ticlopidine is a platelet inhibitor used to prevent thrombosis in patients with cerebrovascular or coronary artery disease. The most common side effects are mild and transitory: diarrhea, dyspepsia, nausea and rashes.
Previtera Antonino M, Pagani Rossella
doaj   +1 more source

Ticlopidine-Induced Cholestatic Inflammatory Hepatitis: New Insights into Pathogenetic Mechanisms of Drug-Related Hepatotoxicity

European Journal of Inflammation, 2006
In immune-induced liver damage the reactive metabolites may covalently bind or alter liver proteins such as cytochrome P450 enzymes, which leads to activation of the immune system. Ticlopidine is an inhibitor of CYP2C19 human liver cytochrome.
I. Kraslova, L. Muchova, L. Vitek, A. Novotny, T. Svestka, R. Bruha   +5 more
doaj   +1 more source